Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
about
Patient-derived tumour xenografts as models for oncology drug developmentMolecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic CancerEGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging.Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomesEGF receptor is required for KRAS-induced pancreatic tumorigenesisIn vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft.Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinibVisualizing epithelial expression of EGFR in vivo with distal scanning side-viewing confocal endomicroscope.More than markers: biological significance of cancer stem cell-defining molecules.Transcriptional dissection of pancreatic tumors engrafted in mice.A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cellsA global insight into a cancer transcriptional space using pancreatic data: importance, findings and flaws.Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancerIntegrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft modelsdmGWAS: dense module searching for genome-wide association studies in protein-protein interaction networksThe relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF).Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.Ready, set, go: the EGF receptor at the pancreatic cancer starting line.Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell linesEfemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice.Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.Error control variability in pathway-based microarray analysis.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaMonoclonal antibodies in the treatment of pancreatic cancer.In vitro models of pancreatic cancer for translational oncology research.Accomplishments in 2008 in the management of localized pancreatic cancer.Somatic variation and cancer: therapies lost in the mix.New biomarkers and targets in pancreatic cancer and their application to treatment.TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.Patient-derived xenografts as tools in pharmaceutical development.The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis.KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling.
P2860
Q24604068-DA1EFA6E-11C0-4DC8-8237-8A9C25F1A9C1Q26765241-53DF5146-FCC4-4614-99E5-76B8FB31817BQ27325591-FC72848C-B18A-4E73-B61E-C8D6D7BB0A0CQ28306591-6570C135-A384-4AF8-A5E4-902A4911D63DQ28584901-A68BA810-3D7C-46A6-8119-550C4F6111E9Q30372076-0F1B7096-EB59-4804-8E65-29BA217300C9Q30422319-68C0BEC0-E69E-4EC3-A603-947BF3B7863CQ30829381-971C3DA0-122A-44CA-B690-E4EE475C1F68Q33661278-E33057C7-76B5-4E8F-93E1-3DDAE9F2E9FFQ33772571-D6E4DDAA-9633-4537-8F63-1B55195A4F92Q33900776-0E7F5EDF-CC11-456B-8670-E96381B3EB9EQ33949308-9E6479A4-769E-4F67-8622-C02BA76FD4B4Q34005862-72B8CF6B-E760-420A-83E7-65D9C97ADC63Q34122822-9E21F512-8EC2-4F21-9878-A13B8104526DQ34177065-B73785BC-6956-49EE-B466-5B844F3596B7Q34201623-ACDA2B23-0439-41B5-85DB-8AE76A2A513DQ34433952-4334A7B6-6276-4678-8A59-F83640DA59FEQ34918878-7EC39ACF-CA4F-40C3-A9D9-9091D86FB472Q35571884-0EBFF90E-A3CB-4AD5-AF21-4C4CBCE17087Q36283930-7A1B41A6-9C97-4532-BD38-71B514AF4803Q36582547-80B5ED15-C7A0-4F09-9798-BF52FED04DF0Q36587976-6899E96C-CD08-4FFD-9268-7F3E04775778Q36982771-3623DE3B-7255-4817-AC3C-DA16C8AD96F4Q37016570-954377DE-D227-4367-B3C1-61FF73C8CCE7Q37059925-834A04E6-2A27-49E0-8C99-DBE8EEF223ACQ37061376-13398E21-3600-427E-AB6F-67EBAC18292EQ37324771-4245E76C-6C28-4B29-AE37-EAF9F88A98F8Q37351498-8DABE199-8833-4B62-AAC8-197A41D3D03CQ37355568-4EFA7AAB-16CA-4811-9153-B35A368D1EBCQ37384842-80D40276-9D02-4A0E-9B21-6723DF9439DBQ37468883-58028C8B-F650-49AF-92D7-877812AF941CQ37885276-A53493B8-CB55-4814-92BC-65F7DF2F83A7Q38021692-2298735A-21CA-4E78-81CC-A99D0D825070Q38204280-2625A6C3-C050-4E03-9880-2829973F6A8DQ38297935-E342F5E5-3048-4A02-996B-30E37D92B465Q38601572-B78A89F4-AAA4-455A-A507-421E49DC83B9Q38732336-40850EBD-B61F-4786-8950-818AFF402A13Q38748123-7186ECDD-5568-40E1-91A7-3167C9813F81Q38755270-C2AF0F14-2EBF-4BAD-AC3B-D4D2876130FCQ38766765-A9A88812-57C5-4E83-BD08-8AF6343FBAF2
P2860
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Coordinated epidermal growth f ...... sitivity in pancreatic cancer.
@en
Coordinated epidermal growth f ...... sitivity in pancreatic cancer.
@nl
type
label
Coordinated epidermal growth f ...... sitivity in pancreatic cancer.
@en
Coordinated epidermal growth f ...... sitivity in pancreatic cancer.
@nl
prefLabel
Coordinated epidermal growth f ...... sitivity in pancreatic cancer.
@en
Coordinated epidermal growth f ...... sitivity in pancreatic cancer.
@nl
P2093
P50
P1433
P1476
Coordinated epidermal growth f ...... sitivity in pancreatic cancer.
@en
P2093
Anirban Maitra
Antonio Jimeno
Begoña Diosdado
Belen Rubio-Viqueira
Fred R Hirsch
Gerrit A Meijer
Jenna Wheelhouse
Jordy Coffa
Marileila Varella-Garcia
N V Rajeshkumar
P304
P356
10.1158/0008-5472.CAN-07-5200
P407
P577
2008-04-01T00:00:00Z